Thijssen et al. Sci Rep. 2021 May 6;11(1):9736.
Through in-house research and partnership programs with pharmaceutical companies and academic groups, we are continuously expanding our extensive portfolio of state-of-the-art biomarkers and antibodies. These qualified antibodies are exclusively available to our partners and collaborators.